Development and Validation of UV Spectrophotometric Area under Curve Method for Quantitative Estimation of Piperacillin and Tazobactam

S.Sangeetha*, M.Kumar, M.V.Kumudhavalli, S.Alexandar and B. Jaykar

Department of Pharmaceutical chemistry, Vinayaka missions College of pharmacy, Salem -636008, Tamilnadu, India.

Abstract: The aim of the present work was to develop an accurate, precise, reproducible and economical UV spectrophotometric Area under Curve method for the estimation Piperacillin and Tazobactam. The UV– spectrophotometric method was carried out using methanol as a solvent. Area under the Curve in the range of 203-218nm and 208-216nm was selected for the analysis of Piperacillin and Tazobactam respectively. The method was validated according to International Conference on Harmonization guidelines and successfully applied to marketed pharmaceutical formulations. The method was found to be linear in the concentration range of 10-50 µg/ml ($r^2 = 0.999$) and 5 - 25 µg/ml ($r^2 = 0.998$) with the regression equation $y = 0.040x + 0.012$ and $y = 0.031x – 0.006$ for Piperacillin and Tazobactam, respectively. Satisfactory values of Percent relative standard deviation for the intra-day and inter-day precision studies indicated that method is precise. The developed method can be used for routine estimation of Piperacillin and Tazobactam in formulation.

Keywords: Area under Curve, Piperacillin, Tazobactam, UV spectrophotometry, Quantitative estimation.

Introduction

Piperacillin/tazobactam is a combination antibiotic containing the extended-spectrum penicillin antibiotic piperacillin and the b-lactamase inhibitor tazobactam and is used to reduce the development of drug-resistant bacteria. Piperacillin [2S- [2a,5a,6b(S*)]]-6-[[[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl] amino]phenyl-acetyl]amino-3,3dimthyl-7-oxo-4-thia-1-azabicyclo -[3.2.0] heptanes-2-carboxylicacid belongs to the ureidopenicillin class and it is used for the treatment of serious infections caused by susceptible strains of microorganisms[1]. Tazobactam (2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazolylmethyl)-4-thia-1-azabicyclo-[3.2.0]heptanes-2-carboxylic acid-4,4-dioxide is used in combination with beta-lactamase antibiotic as antibacterial[2]. Literature review revealed enormous analytical methods were reported for the estimation of Piperacillin and Tazobactam individually or in combination with other drugs ([3-16].) There is no UV spectrophotometric Area under Curve method available in the literature for Piperacillin and Tazobactam. So our aim is to develop and validate a new simple, rapid, accurate, specific and highly sensitive and economical UV spectrophotometric Area under Curve method for estimation of Piperacillin and Tazobactam.

Chemicals and reagents

Piperacillin and tazobactam was a gift sample from MPC division of CDRI. All chemicals used were analytical grade. Methanol (Loba chem Ar grade), in house mill Q water was used throughout the study.

Instrumentation

The UV visible (UV-Vis) spectrophotometric method was developed on a Perkin Elmer Lamba 25 UV-Vis double beam spectrophotometer, with spectral width of 1 nm, wavelength accuracy of 0.5 nm and a pair of 10 mm matched quartz cells. Analytical balance (Shimadzu AUW-120D, Japan) was used for all weightings.

### Preparation of Piperacillin and tazobactam stock and sample solution

Accurately weighed 100 mg of Piperacillin and tazobactam were separately dissolved in methanol to give concentration of 50 µg/mL. The above solutions were used for further analysis.

Sample solution for UV

Sterile preparation of 4 gm of Piperacillin and 0.5 gm of Tazobactam was taken and diluted with 20 mL of sterile water. From above solution 10 mL was taken in 100 mL volumetric flask and make up with 100 mL by methanol. Sonicated for 15 min and filtered through 0.45 µm membrane filter. Further diluted to obtain a concentration of 50 µg/mL.

Selection of wavelength by Area under curve Method

It involves the calculation of integrated value of absorbance with respect to the wavelength between two selected wavelengths λ1 - λ2 and λ3 – λ4. This wavelength range is selected on the basis of repeated observation so as to get the linearity between area under curve and concentration. The solutions of drugs were scanned in the range of 200-400 nm. For Area under Curve method, the sampling wavelength ranges selected for estimation of Piperacillin and Tazobactam were 203-218 nm (λ1-λ2) and 208-216 nm (λ3-λ4) respectively (**Figure 1 & 2**). For determining the concentration of drugs by AUC method, the following equation was used. Amount of each drug was calculated using following formula.

Figure 1: Overlain spectra of Piperacillin

Figure 2: Overlain spectra of Tazobactam

A=absorbance of sample
a= molar absorptivity of sample
b= path length
c=concentration of sample
a=A/bc

Concentration of sample 0.05mg

By substituting mean absorptivity values in the equation given below,

$A_1 = ax_1 + ay_1$
$A_2 = ax_2 + ay_2$
$A_1 = 93.2_{pip} + 512.6_{taz}$-----------(i) at 203-218nm
$A_2 = 146.2_{pip} + 410_{taz}$-------------- (ii) at208-216nm

Where, 93.2 and 146.2 are mean molar absorptivity values of PIP at ($\lambda 1$-$\lambda 2$) and ($\lambda 3$-$\lambda 4$) respectively. 512.6 and 410 are mean absorptivity values of TAZ at ($\lambda 1$-$\lambda 2$) and ($\lambda 3$-$\lambda 4$) respectively.

Where, 0.1184 and 0.1119 are the absorbance of mixed standards A_1 and A_2.

Then substitute value inA_1 andA_2 in above equation (i) and (ii)

$0.1184 = 93.2_{pip} + 512.6_{taz}$

$0.1119 = 146.2_{pip} + 410_{taz}$

Results and discussion

Method validation

The newly developed method was validated according to the International Conference on Harmonisation guidelines with respect to accuracy, precision (repeatability and reproducibility), linearity and range, Limit of Detection (LOD) and Limit of Quantitation (LOQ), and recovery studies.

Recovery

The recovery experiment was carried out at three different levels, i.e. 80, 100, and 120%. The percentage recovery was found to be in the range 93.84 – 97.45 for Piperacillin and 94.52 - 97.64 for Tazobactam. The low values of % relative standard deviation (RSD) are indicative of the accuracy and reproducibility of the method **(Table 1).**

Table 1: Recovery studies for Piperacillin and Tazobactam

Level	Amount Added	Mean Absorbance		Amount Recovery		% Recovery	
		Piperacillin	**Tazobactam**	**Piperacillin**	**Tazobactam**	**Piperacillin**	**Tazobactam**
80%	2.5	0.9985	0.398	24.34	24.98	96.45	97.64
100%	5	1.9971	0.796	49.98	49.63	97.90	96.63
120%	7.5	2.9955	1.194	74.76	74.78	93.84	94.52

Table 2: Intraday precision studies for Piperacillin and Tazobactam

S.No	Absorbance	
	Piperacillin	**Tazobactam**
1	1.991	0.794
2	1.989	0.792
3	1.992	0.794
Mean	1.990	0.793
SD	0.001528	0.001155
%RSD	0.0767	0.1456

Table 3: Interday precision studies for Piperacillin and Tazobactam

S.No	Absorbance					
	Piperacillin			**Tazobactam**		
	Day 1	**Day 2**	**Day 3**	**Day 1**	**Day 2**	**Day3**
1	1.984	1.974	1.970	0.794	0.782	0.778
2	1.982	1.972	1.972	0.794	0.788	0.772
3	1.989	1.976	1.969	0.792	0.779	0.775
Mean	1.985	1.974	1.970	0.793	0.783	0.775
SD	0.003606	0.002	0.001528	0.001155	0.004583	0.003
%RSD	0.1816	0.1013	0.0775	0.1456	0.5853	0.3870

Precision

Precision of the method was evaluated in terms of intra- and inter-day precision. Inter-day precision studies were performed in a same day, but different time intervals. The % RSD values of Piperacillin and Tazobactam were found to be 0.1669% and 0.5777%. Intra-day precision was carried out similarly but in two different days and the %RSD was calculated, the % RSD for Piperacillin and Tazobactam were found to be 1.357% respectively. The % RSD values indicate a good degree of precision within the specified range. This indicates the method is precise (**Table 2 & 3**).

Linearity

It was observed that the optimized method was linear within a specific concentration and range of the drug. The calibration curve was plotted, the linearity range for Piperacillin and Tazobactam were found to be 10 to 50 µg /ml and 5-25 µg /ml. Linear regression equations and correlation coefficient (r^2) were, Piperacillin $Y = 0.040x + 0.012$ ($r^2=0.999$) and Tazobactam $Y = 0.031x + 0.006$ ($r^2=0.998$) (**Table 4 & 5**) (**Figure 3 & 4**).

Table 4: Linearity studies for Piperacillin

Concentration(µg/mL)	Absorbance of Piperacillin	Statistical Analysis of Piperacillim
10	0.412	
20	0.822	Slope =0.040
30	1.245	Correlation coefficient=0.999
40	1.652	
50	1.997	

Table 5: Linearity studies for Tazobactam

Concentration(µg/mL)	Absorbance of Tazobactam	Statistical Analysis of Tazobactam
5	0.154	
10	0.301	Slope =0.015
15	0.465	Correlation coefficient=0.998
20	0.612	
25	0.798	

Figure 3: Linearity of Piperacillin

Figure 4: Linearity of Tazobactam

Limit of Detection and Limit of Quantitation

LOD and LOQ determination is based on the standard deviation of the response and slope. LOD of Piperacillin and Tazobactam was found to be 52.206 µg/mL and 55.66 µg/mL respectively, LOQ of Piperacillin and Tazobactam was found to be 158.2µg/mL and 168.66µg/mL respectively **(Table 6).**

Table 6: LOD and LOQ for Piperacillin Tazobactam

S.No	Concentration (µg/mL)	Absorbance	
		Piperacillin	**Tazobactam**
1	10	0.412	0.154
2	20	0.822	0.301
3	30	1.245	0.465
4	40	1.652	0.612
5	50	1.997	0.798
SD (σ)		0.6328	0.2530
Slope (m)		0.040	0.015
LOD (3.3 × σ / Slope)		52.206 µg/mL	55.66 µg/mL
LOQ (10 × σ / Slope)		158.2 µg/mL	168.66 µg/mL

Conclusion:

The results of the present study indicated that the developed method is simple, precise and cost effective for the simultaneous estimation of for routine quality control analysis of these either in bulk and pharmaceutical formulation.

The developed and validated UV and RP-HPLC method outlined is very obvious, affordable, dynamic, low cost, rapid easy to perform with small sample volume and good repeatability. It can be adopted for the routine quality control analysis of simultaneous determination of Piperacillin and Tazobactam because of good resolution of the chromatographic peaks.

References

1. The Merck Index. 13th ed. Whitehouse station, NJ: Merck & Co.Inc. 2001. p.1337.
2. The Merck Index. 13th ed. Whitehouse station, NJ: Merck & co. Inc. 2001. p.1621.
3. InesToral M, Francisa NR, Fallon N. Simultaneous determination of piperacillin and tazobactam in the pharmaceutical formulation tazonam by derivative spectrophotometry. Journal of the Chilean chemical society 2010; Suppl 57: 1189-1193.
4. Rama KV, Sharmila N, Jayaprakash NK, Haribabu, Satyanaryana PVV. Simultaneous estimation of piperacillin and tazobactam in pharmaceutical formulation by RP HPLC method. Indian Journal Pharmaceutical Science 2013; Suppl 7(1): 127-131.
5. Pai PNS, Rao GK, Murthy MS, Prathibha H. Simultaneous estimation of piperacillin and tazobactam in injection formulations. Indian Journal of Pharmaceutical Science 2006; Suppl 68: 799-801.
6. Sandeep S, Anuj A, Fedelic AT, Amirta C. A review on analytical methodologies for the determination of piperacillin and tazobactam. International Journal of Pharmacy and Pharmaceutical Sciences 2012; Suppl 4: 721-722.
7. NavinKhare K, Rabindra, NK, Raymond LM, DipakNavathar A. Development and validation of spectrophotometric methods for simultaneous estimation of cefepime and tazobactam in combined dosage form by area under curve and q-analysis. International Journal of Institutional Pharmacy and Life Sciences 2012; Suppl; 2(2): 1-8.
8. Lakshmana R, SaiKrishna K, KiranKumar C, Raja T. Simultaneous determination of piperacillin and tazobactam in bulk and pharmaceutical dosage form by RP HPLC method. International Journal of Pharmacy and Pharmaceutical Science 2011; Suppl; 3(2): 852-857.
9. Tersa DC, Arnonolting, Andreas, k, Hartmut D. Determination of free interstitial concentration of piperacillin and tazobactam combination by microdialysis. Journal of Antimicrobial Chemotherapy 1998; Suppl; 42: 769-778.
10. Zhiping L, Qin L, Yi W, Dicao, Chao C. Determiation of free and total piperacillin and tazobatam in plasma by HPLC-MS-MS an adapted method for neonates. Chromatographia 2012; Suppl;75:533-539.
11. Mohammed RR, Mohammed RR, Mojtaba M, Atabak N, Hassan J, Kheirollah G, Mohammed RF. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. International Journal of Antimicrobial Agents 2006; Suppl; 28:122-127.

12.   Arzuga A, Isla A, Gascon AR, Maynar J, Martin A, Solinis MA, Toral D, Pedraz JL. Quantitation and stability of piperacillin and tazobactam in plasma and ultrafiltrate from patients undergoing continuous venovenous hemofiltration by HPLC. Biomed Chromatographia 2005 Suppl; 19(8): 570-578.

13.   Rong C, Quian Q, Sun MR, Quian CY, Zou S, Lan, Wang ML. Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections. European Journal of Drug Metabolism and Pharmokinetics. 2015 Suppl; 10.100713318-015-0276-3.

14.   Barbara A, Murray Ducharme P. Piperacillin and Tazobactam Exhibit Linear Pharmacokinetics after Multiple Standard Clinical Dose. *Antimicrobial agents and Chemotherapy* 1999 Suppl; 43: 1465-1468.

15.   Kolli   Anupama,   Gurupadayya   BM,   Sireesha   T,   Sairam   Aditya.   RP-UFLC-DAD method for the determination of Piperacillin and Tazobactam sodium in bulk and marketed formulations. Journal of Biomedical and Pharmaceutical Research *2016 Suppl;5:89-97.*

16.   Ramalingam P, Rajendran K. Detection of Stability and Degradation of Piperacillin   and Tazobactam in Injectables from In-Patient Wards andPharmacy by RP-HPLC Method Gulf Medical Journal 2014 Suppl; 3(S2):S132-S141.

*****